LEDoxy-SL: A Placebo-Controlled, Double-Blind, Randomized, 24-Month Trial of Six Weeks of Daily Doxycycline Plus Hygiene-Based Essential Care for Reducing Progression of Filarial Lymphedema in Sri Lanka.


Journal

The American journal of tropical medicine and hygiene
ISSN: 1476-1645
Titre abrégé: Am J Trop Med Hyg
Pays: United States
ID NLM: 0370507

Informations de publication

Date de publication:
23 Jul 2024
Historique:
received: 23 01 2024
accepted: 15 03 2024
medline: 24 7 2024
pubmed: 24 7 2024
entrez: 23 7 2024
Statut: aheadofprint

Résumé

Morbidity management of filarial lymphedema remains a challenge even during the post-lymphatic filariasis elimination era in Sri Lanka despite provision of the predominantly hygiene-based WHO Essential Package of Care. Because prior studies have suggested that 6 weeks of doxycycline may reduce progression of limb lymphedema, we conducted a randomized, placebo-controlled, superiority study to evaluate this possibility in Sri Lanka. Patients aged 14 to 65 years with lymphedema in one or both legs received either 200 mg of doxycycline daily for 6 weeks or matching placebo. The primary efficacy endpoint was improvement or lack of progression in lymphedema stage at 24 months postenrollment. Secondary endpoints included change in lymphedema stage at 12 and 24 months, frequency of acute adenolymphangitis episodes, and perceived disability measured by the WHO Disability Assessment Schedule 2.0 (WHODAS 2.0). Training and supplies for limb hygiene were provided throughout the study. Two hundred participants (100 in each arm) with lymphedema of Dreyer stages 1 to 3 were enrolled. By the end of the 2-year study, 29% of the doxycycline patients and 34% of those on placebo showed improvement (i.e., a decrease in lymphedema stage), whereas 11% and 15% of the two groups showed worsening of the lymphedema. Adenolymphangitis rates were comparable in the two groups (43 doxycycline and 38 placebo recipients), although attacks lasted slightly longer in placebo patients (6.5 days versus 5.2 days). In both groups, perceived disability improved initially, with partial rebound in the second year. Only 34 adverse events affecting 24 patients (11%) occurred during the 6-week treatment period. Although doxycycline did not significantly impact lymphedema progression in this study, the results clearly indicate that clinical and personal benefits can be obtained from intensive hygiene management alone.

Identifiants

pubmed: 39043165
doi: 10.4269/ajtmh.24-0050
pii: tpmd240050
doi:
pii:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Thishan Channa Yahathugoda (TC)

Filariasis Research Training and Service Unit, Department of Parasitology, Faculty of Medicine, University of Ruhuna, Galle, Sri Lanka.

Nirmitha Lalindi De Silva (NL)

Filariasis Research Training and Service Unit, Department of Parasitology, Faculty of Medicine, University of Ruhuna, Galle, Sri Lanka.

Janaka Ruben (J)

Filariasis Research Training and Service Unit, Department of Parasitology, Faculty of Medicine, University of Ruhuna, Galle, Sri Lanka.

Sharmini Gunawardena (S)

Department of Parasitology, Faculty of Medicine, University of Colombo, Sri Lanka.

Mirani Vasanthamala Weerasooriya (MV)

Filariasis Research Training and Service Unit, Department of Parasitology, Faculty of Medicine, University of Ruhuna, Galle, Sri Lanka.

John Horton (J)

Tropical Projects, Hitchin, United Kingdom.

Philip Budge (P)

Washington University School of Medicine, St. Louis, Missouri.

Eric Ottesen (E)

Neglected Tropical Disease Support Center, Task Force for Global Health, Decatur. Georgia.

Sarah Mary Sullivan (SM)

Neglected Tropical Disease Support Center, Task Force for Global Health, Decatur. Georgia.

Mariana Stephens (M)

Neglected Tropical Disease Support Center, Task Force for Global Health, Decatur. Georgia.

John Shen (J)

Neglected Tropical Disease Support Center, Task Force for Global Health, Decatur. Georgia.

Ute Klarmann-Schultz (U)

Institute for Medical Microbiology, Immunology and Parasitology (IMMIP), German Centre for Infection Research (DZIF), Bonn-Cologne Site, University Hospital Bonn, Bonn, Germany.

Achim Hoerauff (A)

Institute for Medical Microbiology, Immunology and Parasitology (IMMIP), German Centre for Infection Research (DZIF), Bonn-Cologne Site, University Hospital Bonn, Bonn, Germany.

Joseph Patrick Shott (JP)

Division of Neglected Tropical Diseases, U.S. Agency for International Development, Washington, District of Columbia.

Charles Mackenzie (C)

Neglected Tropical Disease Support Center, Task Force for Global Health, Decatur. Georgia.

Classifications MeSH